Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

NCT06350123 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
DRUG: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
DRUG: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin

Sponsor

AstraZeneca